XTX301 in Patients with Advanced Solid Tumors
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Xilio Development, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT05684965
- Locations
- 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸HealthPartners Frauenshuh Cancer center, St. Louis Park, Minnesota, United States
XTX202 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Xilio Development, Inc.
- Target Recruit Count
- 189
- Registration Number
- NCT05052268
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian- Newport Beach, Newport Beach, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Xilio Development, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT04896697
- Locations
- 🇺🇸
Mayo Clinic Hospital, Rochester, Minnesota, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸City of Hope-Lennar, Irvine, California, United States
© Copyright 2024. All Rights Reserved by MedPath